Ventricular tachycardia
Ventricular tachycardia is a fast heart rhythm that starts in the ventricles, the lower chambers of the heart. MeSH describes it as an abnormally rapid ventricular rhythm, usually faster than 150 beats a minute, that begins in the ventricle itself and not above it. Its onset can be sudden or not. A US government patient page on heart rhythm problems explains tachycardia as a heartbeat faster than normal, and says that an arrhythmia left untreated can damage the heart, the brain and other organs and could be life-threatening. The US label of the medicine amiodarone lists recurrent hemodynamically unstable ventricular tachycardia among its uses.
Also called Tachycardia, Ventricular · VT
- Condition
- In this atlas
Overview
Technical summary
MeSH D017180 (exact), last updated 2023-06-01; the description rests on its scope note, which also says that the wide QRS complexes can be uniform or polymorphic and that the beating of the ventricles may be independent of the beating of the atria (AV dissociation). The general statements about tachycardia, symptoms and untreated arrhythmias come from the MedlinePlus arrhythmia summary and describe arrhythmias as a group, not this rhythm alone. The label statement rests on the amiodarone claims in this atlas (tablet label, adults; injection label, patients refractory to other therapy). No treatment guidance, no frequency figure and no trial result is recorded on this page.
Recognition
A US government patient page on arrhythmias in general lists dizziness or fainting, chest pain or discomfort and shortness of breath among the symptoms, and says you may have no noticeable symptoms. It does not describe ventricular tachycardia on its own.
Burden
No burden claims are published.
Claims and evidence
No claims are published for this condition yet.
Clinical links
Each link reports what one cited claim says about one population. "Evaluated for" means studied, not shown to work. These links do not show that anything is effective or right for you.
-
Claim, not a settled fact Evaluated for this: Amiodarone
Applies to Adult Adults for whom the US label of amiodarone tablets (Pacerone) lists an indication: life-threatening recurrent ventricular fibrillation or recurrent hemodynamically unstable ventricular tachycardia
Population, setting and follow-up
- Adults described in the indications section of the label; the indication sentence is written for adults.
- Prescription medicine in tablet form, as described in the US label; the boxed warning says to initiate it in a clinical setting where continuous electrocardiograms and cardiac resuscitation are available
- United States (label of the US Food and Drug Administration)
- Adults, as the label states
The US label of Pacerone (amiodarone hydrochloride tablets, Upsher-Smith), in the version dated 14 July 2025 in openFDA, lists the tablets for documented, life-threatening recurrent ventricular fibrillation and life-threatening recurrent hemodynamically unstable tachycardia in adults who have not responded to adequate doses of other available antiarrhythmics or when alternative agents cannot be tolerated. The Highlights lines of the label name recurrent ventricular fibrillation and recurrent hemodynamically unstable ventricular tachycardia. The label carries a boxed warning titled pulmonary, hepatic and cardiac toxicity. It says the medicine is intended for use only in patients with the indicated life-threatening arrhythmias because its use is accompanied by substantial toxicity, that it can cause pulmonary toxicity and liver toxicity that can be fatal, and that it can exacerbate arrhythmias.Limitations. This claim records what the label says it is indicated for. It is not a finding about how well the medicine works, and no trial result is recorded for it in this atlas. Only the indications, the main lines of the boxed warning and the first sentence on mechanism were read; contraindications, doses, interactions and other warnings were not recorded. The label sentence says "unstable tachycardia" without the word ventricular; the ventricular wording is in the Highlights line. Labels change: openFDA also lists repackager copies and other amiodarone labels with other text. openFDA's own disclaimer says not to rely on it for decisions about medical care.
-
Claim, not a settled fact Evaluated for this: Flecainide
Applies to Recipient not specified Patients with paroxysmal supraventricular tachycardia, paroxysmal atrial fibrillation or flutter, or life-threatening ventricular arrhythmias, as described in the US label of flecainide acetate tablets
Population, setting and follow-up
- Patients described in the indications section of the label: patients without structural heart disease who have paroxysmal supraventricular tachycardias or paroxysmal atrial fibrillation or flutter with disabling symptoms, and patients with documented life-threatening ventricular arrhythmias. The passages read do not state an age range.
- Prescription medicine, as described in the US label
- United States (label of the US Food and Drug Administration)
- Not stated in the label passages read
- Gestational age Not reported
- Postnatal age Not reported
The US label of flecainide acetate tablets (Hikma Pharmaceuticals USA Inc., application ANDA076278; the version dated 2024-12-04 in openFDA) describes flecainide as an antiarrhythmic drug. For patients without structural heart disease it lists prevention of paroxysmal supraventricular tachycardias, including atrioventricular nodal reentrant tachycardia, and of paroxysmal atrial fibrillation or flutter, each when associated with disabling symptoms. It also lists prevention of documented ventricular arrhythmias, such as sustained ventricular tachycardia, that in the physician's judgment are life-threatening. It states that there is no evidence from controlled trials that flecainide acetate favorably affects survival or the incidence of sudden death.Limitations. This claim records what one US generic label says the medicine is indicated for. It is not a finding about how well the medicine works, and no trial result is recorded for it in this atlas. The label's indications section also carries usage statements on chronic atrial fibrillation and on where treatment for sustained ventricular tachycardia begins; they are not recorded here. Contraindications, other warnings, interactions, the label's pediatric statement and dosing were not recorded. The brand label (Tambocor) was not read, and openFDA lists other flecainide labels with different dates. openFDA's own disclaimer says not to rely on it for decisions about medical care.
-
Claim, not a settled fact Evaluated for this: Propafenone
Applies to Recipient not specified Patients with paroxysmal atrial fibrillation or flutter, paroxysmal supraventricular tachycardia, or life-threatening ventricular arrhythmias, as described in the US label of propafenone hydrochloride tablets
Population, setting and follow-up
- Patients described in the indications section of the label: patients without structural heart disease who have paroxysmal atrial fibrillation or flutter, or paroxysmal supraventricular tachycardia, with disabling symptoms, and patients with documented life-threatening ventricular arrhythmias. The passages read do not state an age range.
- Prescription medicine, as described in the US label
- United States (label of the US Food and Drug Administration)
- Not stated in the label passages read
- Gestational age Not reported
- Postnatal age Not reported
The US label of propafenone hydrochloride tablets (ANI Pharmaceuticals, Inc., application ANDA076550; the version dated 2025-09-12 in openFDA) describes propafenone as an antiarrhythmic. It lists prolonging the time to recurrence of paroxysmal atrial fibrillation or flutter, and of paroxysmal supraventricular tachycardia, each associated with disabling symptoms in patients without structural heart disease, and treatment of documented ventricular arrhythmias, such as sustained ventricular tachycardia, that in the judgment of the physician are life-threatening. It states that the effect of propafenone on mortality has not been determined.Limitations. This claim records what one US generic tablet label says the medicine is indicated for. It is not a finding about how well the medicine works, and no trial result is recorded for it in this atlas. The label also lists usage considerations (for example, that use in permanent atrial fibrillation has not been evaluated); those are the label's statements and are not repeated as advice. Extended-release capsule labels, which state a narrower atrial fibrillation indication, were not read. Contraindications, other warnings, interactions, the label's pediatric statement and dosing were not recorded. openFDA lists other propafenone labels with different dates, and its own disclaimer says not to rely on it for decisions about medical care.
-
Claim, not a settled fact Evaluated for this: Sotalol
Applies to Recipient not specified Patients with life-threatening ventricular arrhythmias, or with highly symptomatic atrial fibrillation or flutter who are in sinus rhythm, as described in the US label of Betapace and Betapace AF
Population, setting and follow-up
- Patients described in the indications section of the label: patients with documented life-threatening ventricular arrhythmias such as sustained ventricular tachycardia, and patients with highly symptomatic atrial fibrillation or flutter who are currently in sinus rhythm. The passages read do not state an age range.
- Prescription medicine, as described in the US label
- United States (label of the US Food and Drug Administration)
- Not stated in the label passages read
- Gestational age Not reported
- Postnatal age Not reported
The US label of Betapace and Betapace AF (sotalol hydrochloride tablets, Legacy Pharma USA, Inc., application NDA019865; the version dated 2024-12-16 in openFDA) describes the medicine as an antiarrhythmic. It lists the treatment of documented, life-threatening ventricular arrhythmias, such as sustained ventricular tachycardia, and the maintenance of normal sinus rhythm (delay in time to recurrence of atrial fibrillation or flutter) in patients with highly symptomatic atrial fibrillation or flutter who are currently in sinus rhythm. It states that the medicine has not been shown to enhance survival in patients with life-threatening ventricular arrhythmias.Limitations. This claim records what one US label says the medicine is indicated for. It is not a finding about how well the medicine works, and no trial result is recorded for it in this atlas. The label also gives limitations of use for the atrial fibrillation indication (reserve for highly symptomatic patients); those are the label's statements and are not repeated as advice. Contraindications, other warnings, the label's pediatric statements and dosing were not recorded. The oral solution (Sotylize) and generic labels were not read. openFDA's own disclaimer says not to rely on it for decisions about medical care.
Registry records
Assembled by a program from ClinicalTrials.gov. No person wrote or checked these pages, and they are counted apart from the pages that people wrote. Lists of trials come from the registry's own coding and may miss trials.
Registry trials 58
Record details
- Record id
cardio:ventricular-tachycardia- Content hash
dbd0eece17d5c42401739432e3ba83eab56d838f883ed18b5cb276190a852bc8